

## PRESS RELEASE

---

# Camurus to present at Jefferies 2023 Healthcare Conference London

**Lund, Sweden — 1 November 2023** — Camurus (Nasdaq Stockholm; CAMX), a commercial-stage pharmaceutical company developing innovative medications for severe and chronic diseases, today announced that Fredrik Tiberg, President and Chief Executive Officer, will participate in a fireside chat about the company's business progress and R&D pipeline developments at Jefferies 2023 Healthcare Conference in London on 15 November at 8:30-8:55 am local time (GMT).

A live webcast of the presentation can be accessed via:  
<https://wsw.com/webcast/jeff287/camx.st/2248776>

### For more information

Fredrik Joabsson, Chief Business Development Officer  
Tel. +46 (0)70 776 17 37  
[ir@camurus.com](mailto:ir@camurus.com)

### About Camurus

*Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).*

This information was submitted for publication at 8:00 am CET on 1 November 2023.